| __timestamp | Mesoblast Limited | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 54170000 | 10811000 |
| Thursday, January 1, 2015 | 65378000 | 33001000 |
| Friday, January 1, 2016 | 52263000 | 64936000 |
| Sunday, January 1, 2017 | 35072000 | 99909000 |
| Monday, January 1, 2018 | 27415000 | 127724000 |
| Tuesday, January 1, 2019 | 36983000 | 161524000 |
| Wednesday, January 1, 2020 | 50918000 | 182933000 |
| Friday, January 1, 2021 | 63586000 | 219982000 |
| Saturday, January 1, 2022 | 57967000 | 278139000 |
| Sunday, January 1, 2023 | 53107000 | 309799000 |
| Monday, January 1, 2024 | 23626000 |
Data in motion
In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Ultragenyx Pharmaceutical Inc. and Mesoblast Limited from 2014 to 2023. Ultragenyx, a leader in rare disease treatments, has seen its SG&A expenses skyrocket by over 2,700% from 2014 to 2023, reflecting its aggressive growth strategy. In contrast, Mesoblast, known for its regenerative medicine, experienced a more modest 56% increase over the same period. Notably, Ultragenyx's expenses surpassed Mesoblast's by nearly 500% in 2023, highlighting its expansive operational scale. However, Mesoblast's expenses showed a decline in 2024, indicating potential cost optimization or strategic shifts. This financial snapshot underscores the diverse strategies these companies employ in navigating the biotech landscape.
Eli Lilly and Company and Mesoblast Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Mesoblast Limited
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
Sarepta Therapeutics, Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?
Walgreens Boots Alliance, Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Madrigal Pharmaceuticals, Inc. and Mesoblast Limited
Selling, General, and Administrative Costs: Corcept Therapeutics Incorporated vs Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: Cytokinetics, Incorporated vs Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and MorphoSys AG
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Viking Therapeutics, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
PTC Therapeutics, Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?